Sir Brian Souter backs cancer drug firm's Â£1.8m fundraising
Stagecoach tycoon Sir Brian Souter has backed a Â£1.8 million fundraising by a Borders-based gene therapy specialist.
The cash injection for Selkirk-headquarter Ryboquin also brought in funding from new investor Brian Kennedy and existing shareholders including the Scottish Investment Bank and Tri Capital.
• READ MORE: Pharma business seeking £10m for cancer treatment
Kennedy is joining the board of Ryboquin, which was founded in 2013 and focuses on commercialising patented intellectual property in the area of delivering gene therapy, primarily in the field of human cancer medicine.
• READ MORE: Positive moves provide shot in arm for life sciences
“I am delighted to be part of Ryboquin and to be working with the team that could make great progress in the treatment of cancer and other diseases,” said Kennedy.
The firm said it would use the fresh funding for corporate expansion and to boost its scientific development.
Executive chairman Paul Murray said: “The support from existing shareholders and the investment by Brian Kennedy and Sir Brian Souter, two esteemed leaders and hugely successful businessmen, is testimony to the potential of Ryboquin and to the work we are undertaking in the field of cancer gene therapy drug development.”